Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2005

Filing Date
Filed March 10, 2006
Period End
December 31, 2005
Security
IDXX
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed March 10, 2006. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' fiscal 2005 10-K shows a company that grew revenue 16% to $638.1 milliona, led by its Companion Animal Group (CAG), which rose 16% to $520.8 million on strong growth in reference laboratory services (up 32%, largely from acquisitions) and instruments and consumables (up 10%).

Operating income rose 7% to $115.3 millionb, but operating margin compressed from 19.7% to 18.1%, reflecting acquisition integration costs, amortization of acquired intangibles, and continued investment in sales, customer service and marketing. Diluted EPS increased 5% to $2.30 despite a higher effective tax rate of 34.2% (versus 29.7% in 2004, which benefited from a one-time IRS audit resolution), and net income was roughly flat at $78.3 million. The balance sheet and cash flow picture is solid.

Operating cash flow rose to $116.6 millionc, and the company repurchased about 1.99 million shares for $123.8 million, reducing the share count meaningfully (weighted average diluted shares fell from 35.8 million to 34.1 million). Cash and short-term investments declined to $132.7 million, and stockholders' equity fell to $369.0 million because buybacks exceeded earnings. Debt is negligible at $0.55 million.

Looking ahead, investors should weigh several items: share-based compensation expensing under SFAS 123(R) begins in 2006 and will pressure margins; the company's VetTest slide supply is concentrated with Ortho and carries a $92.7 milliond minimum purchase commitment through 2010; the next-generation chemistry analyzer is not expected before late 2007; and roughly 34% of revenue is international. Distributor purchasing patterns and the consolidation of U.S. distributors (two of which now represent 10% of revenue) add quarterly volatility, and the company reports no material legal proceedings.

Key Highlights

  1. Revenue grew 16% to $638.1 million, with CAG contributing $520.8 million (up 16%), Water up 7% to $56.8 million, and Food Diagnostics Group up 28% to $60.5 million.
  2. Reference laboratory and consulting services was the fastest-growing CAG line, up 32% to $156.4 million, with roughly 23% of that growth coming from laboratories acquired in late 2004 and 2005.
  3. Gross margin held roughly flat at 50.6% (versus 50.8%), while operating margin contracted to 18.1% from 19.7% due to acquisition integration costs, intangible amortization, and expanded sales and marketing spending.
  4. Diluted EPS rose 5% to $2.30, but net income was essentially flat at $78.3 million because the effective tax rate increased to 34.2% from 29.7%, which had been reduced in 2004 by a one-time IRS audit resolution.
  5. The company repurchased 1,993,000 shares for $123.8 million in 2005, lowering diluted weighted shares by about 5% and leaving 2.05 million shares remaining under the 16 million-share authorization.
  6. Operating cash flow increased to $116.6 million, but cash and short-term investments fell to $132.7 million and stockholders' equity declined to $369.0 million, with total debt of only $0.6 million.
  7. Key risks include single-source supply from Ortho (VetTest slides, with $92.7 million in minimum purchases through 2010), a next-generation analyzer not expected until late 2007, 34% international revenue exposure, and SFAS 123(R) expense recognition starting in 2006.

Frequently Asked Questions

  1. Why did operating margin decline even though revenue grew 16%?

    Operating income rose 7% to $115.3 million, but growth lagged revenue. Management attributes the margin decline to acquisition integration costs for businesses acquired in late 2004 and 2005 (including the centralization of European production animal diagnostics in Switzerland), amortization of intangibles from those acquisitions, and an expansion of CAG's sales, customer service and marketing organization. Newly acquired reference laboratories typically run at lower margins for a year or more, which dilutes the consolidated margin in the near term.

  2. How did the effective tax rate change, and why does it matter for earnings comparisons?

    The effective tax rate rose to 34.2% in 2005 from 29.7% in 2004. The 2004 rate was lower because of the resolution of an IRS audit through 2001, which reduced previously accrued taxes, and the release of a valuation allowance on international deferred tax assets. The 2005 rate also includes a $1.0 million charge tied to repatriating $30.0 million under the American Jobs Creation Act. Because of this, pre-tax income grew about 7% but net income was essentially flat, so the 2004 comparison base is inflated by one-time benefits.

  3. What is the company's exposure to its VetTest slide supplier, and what changes are coming?

    VetTest slides are supplied exclusively by Ortho (a Johnson & Johnson subsidiary) under agreements running through December 31, 2020, and IDEXX must purchase its requirements from Ortho. It has a minimum purchase commitment of $92.7 million through 2010. IDEXX is co-developing a next-generation chemistry analyzer based on Ortho's dry-slide technology, which it does not expect to be commercially available until the latter part of 2007. Management believes the Ortho contract will not produce a loss, but the single-source relationship remains a concentration risk.

  4. What should investors expect for 2006 given the accounting and capital allocation changes?

    Beginning January 1, 2006, IDEXX adopted SFAS 123(R), which requires expensing share-based compensation. Management expects this to weigh on gross profit percentages and operating margins across all segments, with about $16.6 million of unvested award cost to be recognized from 2006 through 2010 (roughly half in 2006). On capital allocation, the company has a 2006 capital budget of about $37.0 million and plans to buy its headquarters building for $18.0 million less the mortgage, plus an estimated $20 million over two years for renovation. Continued buybacks are possible under the remaining 2.05 million-share authorization, but the company has never paid a cash dividend and has no present intention to do so.